National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy
Humanigen is providing lenzilumab for the study, which is fully funded by NIH.
- Humanigen is providing lenzilumab for the study, which is fully funded by NIH.
- ACTIV-5/BET is being conducted in collaboration with the NIHs public-private partnership Accelerating COVID-19 Therapeutic Innovations and Vaccines ( ACTIV ) program.
- We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
- You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.